The invention further relates to a DGAT inhibitor of formula

[Image Omitted]

including any stereochemically isomeric form thereof, wherein A represents CH or N; the dotted line represents an optional bond in case A represents a carbon atom; X represents â€”NR^xâ€”C(â• O)â€”; â€”Zâ€”C(â• O)â€”; â€”Zâ€”NR^xâ€”C(â• O)â€”; â€”S(â• O)p-; â€”C(â• S)â€”; â€”NR^xâ€”C(â• S)â€”; â€”Zâ€”C(â• S)â€”; â€”Zâ€”NR^xâ€”C(â• S)â€”; â€”Oâ€”C(â• O)â€”; â€”C(â• O)â€”C(â• O)â€”; R¹represents a 5-membered monocyclic heterocycle containing at least 2 heteroatoms; a 6-membered aromatic monocyclic heterocycle; or a 5-membered heterocycle containing at least 2 heteroatoms fused with phenyl, cyclohexyl or a 5- or 6-membered heterocycle; wherein each of said heterocycles may optionally be substituted; R²represents R³; R³represents C_3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or a 6-membered aromatic heterocycle containing 1 or 2 N atoms, wherein said C_3-6cycloalkyl, phenyl, naphtalenyl, 2,3-dihydro-1,4-benzodioxinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzofuranyl or 6-membered aromatic heterocycle may optionally be substituted; a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.

The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.